LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article ; Online: Comparing the expression of MiR-223-NLRP3-IL-1β axis and serum IL-1β levels in patients with severe COVID-19 and healthy individuals.

    Houshmandfar, Sheyda / Khodadadi, Ali / Mahmoudian-Sani, Mohammad-Reza / Nashibi, Roohangiz / Rashno, Mohammad

    Immunobiology

    2023  Volume 228, Issue 5, Page(s) 152710

    Abstract: Background and aim: The hyperactive nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 (NLRP3) inflammasome in the course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a key factor for cytokine ... ...

    Abstract Background and aim: The hyperactive nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 (NLRP3) inflammasome in the course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a key factor for cytokine storm, chronic inflammation, and mortality in infected patients. On the subject of the regulation of the NLRP3-inflammasome activation, micro-ribonucleic acid (RNA)-223 (miR-223), among the major RNA molecules, has been thus far investigated in some inflammatory diseases along with interleukin-1 beta (IL-1β) and NLRP3. Against this background, the present study aimed to compare healthy individuals and patients with severe COVID-19 with reference to the alterations in the expression of the miR-223, NLRP3, and IL-1β axis and the serum IL-1β levels.
    Methods: In total, 40 patients with severe COVID-19, admitted to the Infectious Ward of Razi Hospital, Ahvaz, Iran, who were homogenous in terms of age (40 years old) and gender, were selected based on the inclusion and exclusion criteria. The real-time polymerase chain reaction (RT-PCR) technique was then applied to assess the expression of the miR-223, NLRP3, and IL-1β genes, and enzyme-linked immunosorbent assay (ELISA) was then utilized to evaluate the serum IL-1β levels, using patients' blood samples. Moreover, inflammatory biochemical markers of the participants were collected and recorded RESULTS: According to the study results, the IL-1β expression was 3.9 times higher in the patients with COVID-19, compared with the control group (p = 0.0005). The NLRP3 expression was also 6.04 times greater in the infected patients, compared with the healthy individuals (p < 0.0001). On the other hand, the miR-223 expression was 5.37 times lower in the case group, compared with the controls (p = 0.04).
    Conclusion: The study findings indicated the potential role of miR-223 and the dysregulation of NLRP3 inflammasome followed by IL-1β, as a regulatory factor in the pathogenesis of COVID-19, like that in other inflammatory diseases.
    MeSH term(s) Humans ; Adult ; Inflammasomes/metabolism ; NLR Family, Pyrin Domain-Containing 3 Protein/genetics ; NLR Family, Pyrin Domain-Containing 3 Protein/metabolism ; Interleukin-1beta/genetics ; Interleukin-1beta/metabolism ; COVID-19 ; SARS-CoV-2/genetics ; MicroRNAs/genetics
    Chemical Substances Inflammasomes ; NLR Family, Pyrin Domain-Containing 3 Protein ; Interleukin-1beta ; MicroRNAs ; MIRN223 microRNA, human
    Language English
    Publishing date 2023-07-17
    Publishing country Netherlands
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 563292-4
    ISSN 1878-3279 ; 0171-2985
    ISSN (online) 1878-3279
    ISSN 0171-2985
    DOI 10.1016/j.imbio.2023.152710
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: miRNA-223 as a regulator of inflammation and NLRP3 inflammasome, the main fragments in the puzzle of immunopathogenesis of different inflammatory diseases and COVID-19.

    Houshmandfar, Sheyda / Saeedi-Boroujeni, Ali / Rashno, Mohammad / Khodadadi, Ali / Mahmoudian-Sani, Mohammad-Reza

    Naunyn-Schmiedeberg's archives of pharmacology

    2021  Volume 394, Issue 11, Page(s) 2187–2195

    Abstract: Millions of people around the world are involved with COVID-19 due to infection with SARS-CoV-2. Virological features of SARS-CoV-2, including its genomic sequence, have been identified but the mechanisms governing COVID-19 immunopathogenesis have ... ...

    Abstract Millions of people around the world are involved with COVID-19 due to infection with SARS-CoV-2. Virological features of SARS-CoV-2, including its genomic sequence, have been identified but the mechanisms governing COVID-19 immunopathogenesis have remained uncertain. miR-223 is a hematopoietic cell-derived miRNA that is implicated in regulating monocyte-macrophage differentiation, neutrophil recruitment, and pro-inflammatory responses. The miR-223 controls inflammation by targeting a variety of factors, including TRAF6, IKKα, HSP-70, FOXO1, TLR4, PI3K/AKT, PARP-1, HDAC2, ITGB3, CXCL2, CCL3, IL-6, IFN-I, STMN1, IL-1β, IL-18, Caspase-1, NF-κB, and NLRP3. The key role of miR-223 in regulating the inflammatory process and its antioxidant and antiviral role can suggest this miRNA as a potential regulatory factor in the process of COVID-19 immunopathogenesis.
    MeSH term(s) Animals ; COVID-19/genetics ; COVID-19/immunology ; COVID-19/pathology ; Humans ; Inflammasomes/genetics ; Inflammasomes/immunology ; Inflammation/genetics ; Inflammation/immunology ; Inflammation/pathology ; MicroRNAs/genetics ; NLR Family, Pyrin Domain-Containing 3 Protein/genetics
    Chemical Substances Inflammasomes ; MIRN223 microRNA, human ; MicroRNAs ; NLR Family, Pyrin Domain-Containing 3 Protein ; NLRP3 protein, human
    Language English
    Publishing date 2021-09-30
    Publishing country Germany
    Document type Journal Article ; Review
    ZDB-ID 121471-8
    ISSN 1432-1912 ; 0028-1298
    ISSN (online) 1432-1912
    ISSN 0028-1298
    DOI 10.1007/s00210-021-02163-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Tranilast: a potential anti-Inflammatory and NLRP3 inflammasome inhibitor drug for COVID-19.

    Saeedi-Boroujeni, Ali / Mahmoudian-Sani, Mohammad-Reza / Nashibi, Roohangiz / Houshmandfar, Sheyda / Tahmaseby Gandomkari, Sima / Khodadadi, Ali

    Immunopharmacology and immunotoxicology

    2021  Volume 43, Issue 3, Page(s) 247–258

    Abstract: SARS-CoV-2 is a type of beta-CoV that develops acute pneumonia, which is an inflammatory condition. A cytokine storm has been recognized as one of the leading causes of death in patients with COVID-19. ALI and ARDS along with multiple organ failure have ... ...

    Abstract SARS-CoV-2 is a type of beta-CoV that develops acute pneumonia, which is an inflammatory condition. A cytokine storm has been recognized as one of the leading causes of death in patients with COVID-19. ALI and ARDS along with multiple organ failure have also been presented as the consequences of acute inflammation and cytokine storm. It has been previously confirmed that SARS-CoV, as another member of the beta-CoV family, activates NLRP3 inflammasome and consequently develops acute inflammation in a variety of ways through having complex interactions with the host immune system using structural and nonstructural proteins. Numerous studies conducted on Tranilast have further demonstrated that the given drug can act as an effective anti-chemotactic factor on controlling inflammation, and thus, it can possibly help the improvement of the acute form of COVID-19 by inhibiting some key inflammation-associated transcription factors such as NF-κB and impeding NLRP3 inflammasome. Several studies have comparably revealed the direct effect of this drug on the prevention of inappropriate tissue's remodeling; inhibition of neutrophils, IL-5, and eosinophils; repression of inflammatory cell infiltration into inflammation site; restriction of factors involved in acute airway inflammation like IL-33; and suppression of cytokine IL-13, which increase mucosal secretions. Therefore, Tranilast may be considered as a potential treatment for patients with the acute form of COVID-19 along with other drugs.
    MeSH term(s) Anti-Inflammatory Agents/therapeutic use ; COVID-19/drug therapy ; COVID-19/immunology ; COVID-19/pathology ; Humans ; Inflammasomes/immunology ; NLR Family, Pyrin Domain-Containing 3 Protein/immunology ; SARS-CoV-2/immunology ; ortho-Aminobenzoates/therapeutic use
    Chemical Substances Anti-Inflammatory Agents ; Inflammasomes ; NLR Family, Pyrin Domain-Containing 3 Protein ; NLRP3 protein, human ; ortho-Aminobenzoates ; tranilast (HVF50SMY6E)
    Language English
    Publishing date 2021-05-21
    Publishing country England
    Document type Journal Article ; Review ; Video-Audio Media
    ZDB-ID 807033-7
    ISSN 1532-2513 ; 0892-3973
    ISSN (online) 1532-2513
    ISSN 0892-3973
    DOI 10.1080/08923973.2021.1925293
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Interleukin-22 and intestinal homeostasis: Protective or destructive?

    Shohan, Mojtaba / Dehghani, Razieh / Khodadadi, Ali / Dehnavi, Sajad / Ahmadi, Reza / Joudaki, Nazanin / Houshmandfar, Sheyda / Shamshiri, Marziye / Shojapourian, Samira / Bagheri, Nader

    IUBMB life

    2020  Volume 72, Issue 8, Page(s) 1585–1602

    Abstract: Interleukin (IL)-22 is a member of IL-10 family cytokines with various immunologic functions. As its name implies, IL-22 is known to be secreted mainly by Th22 cells, a recently discovered lineage of CD4+ T cells. Also, Th17, Th1, natural killer cells, ... ...

    Abstract Interleukin (IL)-22 is a member of IL-10 family cytokines with various immunologic functions. As its name implies, IL-22 is known to be secreted mainly by Th22 cells, a recently discovered lineage of CD4+ T cells. Also, Th17, Th1, natural killer cells, γδT cells, and innate immune cells along with some nonlymphoid cells have been confirmed as secondary cellular sources of IL-22. Different cell types such as bronchial and intestinal epithelial cells, keratinocytes, hepatocytes, dermal fibroblasts, and tubular epithelial cells are affected by IL-22. Both pathologic and protective roles have been attributed to IL-22 in maintaining gut homeostasis and inflammation. According to the latest fast-growing investigations, IL-22 is significantly involved in various pathologies including allergic diseases, infection, autoimmunity, and cancer development. Regulating gut immune responses, barrier integrity, and inflammation is dependent on a diverse complex of cytokines and mediators which are secreted by mucosal immune cells. Several investigations have been designed to recognize the role of IL-22 in gastrointestinal immunity. This article tries to discuss the latest knowledge on this issue and clarify the potential of IL-22 to be used in the future therapeutic approaches of intestinal disorders including inflammatory bowel diseases and colon cancer.
    MeSH term(s) Gastrointestinal Tract/immunology ; Gastrointestinal Tract/metabolism ; Homeostasis/genetics ; Homeostasis/immunology ; Humans ; Immunity, Innate/genetics ; Inflammatory Bowel Diseases/genetics ; Inflammatory Bowel Diseases/immunology ; Interleukin-10/genetics ; Interleukin-10/immunology ; Interleukins/genetics ; Interleukins/immunology ; Intestinal Mucosa/immunology ; Th17 Cells/metabolism ; Interleukin-22
    Chemical Substances IL10 protein, human ; Interleukins ; Interleukin-10 (130068-27-8)
    Language English
    Publishing date 2020-05-04
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 1492141-8
    ISSN 1521-6551 ; 1521-6543
    ISSN (online) 1521-6551
    ISSN 1521-6543
    DOI 10.1002/iub.2295
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top